James Chen, CEO, Agno Pharmaceuticals, outlined the company’s expansion activity in small-molecule active pharmaceutical ingredients (APIs) and GMP intermediates and drug-product development and manufacturing, at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

The company announced in January (January 2026), the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon, from Actylis. The site is focused on small-molecule API development and manufacturing. The site is anchored by a 16,000-square-foot R&D lab facility as well as a newly constructed 30,000-square-foot manufacturing facility, equipped with GMP infrastructure supporting early-phase to late-phase clinical API production. Under Actylis, the Eugene site received investment to expand and upgrade its GMP manufacturing operations

Ango Pharma is headquartered in Bethlehem, Pennyslyvania, and the company is also expanding drug-product manufacturing at its site through an aseptic fill line expansion.